What’s the fate of BeiGene’s PD-1 inhibitor after Bristol-Myers Squibb’s buyout of Celgene?
In an interview at the ASCO meeting, BeiGene chief adviser Eric Hedrick said the company is well-prepared for when it likely regains global rights to tislelizumab.